Amarin Corporation Plc · NASDAQ:AMRN
Amarin — Q1 2025 Earnings Presentation
12 slides from Amarin's earnings presentation, May 7, 2025
Slide 1: First Quarter 2025 Financial Results & Business Update
First Quarter 2025 Financial Results & Business Update Conference Call May 7, 2025
Slide 2: Forward-Looking Statements & Disclaimer
Forward-Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, res
Slide 3: Today's Agenda
Today’s Agenda 01 FIRST QUARTER 2025 STATE OF THE BUSINESS: AN UPDATE Aaron Berg, President & CEO 02 FIRST QUARTER 2025 FINANCIAL RESULTS Peter Fishman, SVP, Chief Financial Officer 03 CLOSING REMARKS Aaron Berg, President & CEO 04 Q&A
Slide 4: First Quarter 2025 State of the Business: An Update
01 FIRST QUARTER 2025 STATE OF THE BUSINESS: AN UPDATE Aaron Berg President & CEO
Slide 5: Q1 2025: Progress Update
BUSINESS UPDATE Q1 2025: PROGRESS UPDATE OPERATIONAL HIGHLIGHTS FINANCIAL HIGHLIGHTS Europe: Completed 1-for-20 ADS Ratio Change Realized sequential growth in In-market demand across all markets where VAZKEPA launched, driven primarily by Spain, UK & CEE Regained compliance with Nasdaq minimum
Slide 6: First Quarter 2025 Financial Results
02 FIRST QUARTER 2025 FINANCIAL RESULTS Peter Fishman Senior Vice President, Chief Financial Officer
Slide 7: Q1 2025: P&L Highlights
FINANCIAL RESULTS Q1 2025: P&L HIGHLIGHTS Q1 ’25 TOTAL REVENUE OF $42.0M Q1 ‘25 OPERATING EXPENSES of $41.9M • US: $35.7 million; ~26% reduction • ROW: Nominal contribution due to • $41.9 million; 8% reduction year-over-year due to continued year-over-year due to lower NSP timing of supply shipments
Slide 8: Q1 2025: Balance Sheet Highlights
FINANCIAL RESULTS Q1 2025: BALANCE SHEET HIGHLIGHTS Cash Balance of $281.8M; -9% Decline Since the End of 2022 Reflects Efforts of Prudent Cash Deployment $321M $321M Q1 2025 TOTAL CASH $311M $313M $305M $308M $307M $306M POSITION OF $282 MILLION $294M AND NO DEBT $282M • Continued focus on expense
Slide 9: Closing Remarks
03 CLOSING REMARKS Aaron Berg President & CEO
Slide 10: 2025: Amarin Priorities
CLOSING REMARKS 2025: AMARIN PRIORITIES ONGOING: • Drive growth in access and revenue in Europe and Rest of World markets. CVD Remains #1 Killer Worldwide1 • Drive efficient VASCEPA U.S. revenue generation. Significant and urgent need for proven therapeutic interventions • Support research that rein
Slide 11: Q&A
04 Q&A
Slide 12: Thank You
Vascepa Vazkepa (icosapent ethyl) (icosapent ethyl) THANK YOU